Vulvovaginal candidiasis (VVC) is an opportunistic fungal infection caused by Candida species that affects $75% of otherwise healthy women of childbearing age in the United States [1] . Several factors predispose women to acute VVC, most of which involve elevated hormone levels (e.g., pregnancy, the luteal phase of the menstrual cycle, and use of oral contraceptives or hormone replacement therapy) or antibiotic use. Another 5%-10% of women are seemingly healthy and suffer from recurrent VVC (RVVC; >3 episodes/year) without any known predisposing factors [1] . It has been postulated that an undefined innate and/or adaptive immunodeficiency or dysfunction is responsible for RVVC.
Although cell-mediated immunity (CMI) by Th1-type T cells is considered to be the predominant host defense mechanism against mucosal Candida albicans infections, the role of CMI with regard to Candida at the vaginal mucosa has recently been challenged. First, several clinical studies have demonstrated that most women experience RVVC despite having normal levels of Candida-specific Th1-type CMI in the peripheral circulation (reviewed in [2] ). Second, experimental studies that have used an estrogen-dependent murine model of vaginal candidiasis have paralleled the clinical findings [2] . Furthermore, our most recent data suggest that some form of immunoregulation may inhibit a more profound CMI response of systemic or local origin against vaginal candidiasis [3, 4] . Humoral immunity against vaginal candidiasis is equally controversial. Experimental studies in mice have provided some evidence for protection, using Candida-specific antibodies [5] , but, clinically, women with RVVC have normal or elevated levels of Candida-specific antibodies [6] . With regard to innate resistance, although polymorphonuclear leukocytes (PMNL) have significant killing activity against Candida in vitro (reviewed in [7] ), PMNL do not affect Candida at the murine vaginal mucosa [8] . Although macrophages that also have significant killing activity against Candida in vitro [7] have not been investigated functionally at the vaginal mucosa, NK cells have been shown to have little to no anti-Candida activity in vivo or in vitro against Candida [9] . In contrast, we have recently shown that primary vaginal epithelial cells from mice and nonhuman primates, as well as human oral epithelial cells and epithelial cell lines, have the ability to inhibit the growth of Candida in vitro [10, 11] . Given that epithelial cells are the host cells with the most contact with C. albicans at mucosal tissues, we have postulated that epithelial cells may represent an important local anti-Candida host defense mechanism. Epithelial cell-mediated anti-Candida activity, as it is currently understood, involves cell contact between a carbohydrate moiety on the epithelial cells and Candida, with no role for soluble factors, phagocytosis, or oxidative killing [12] . Significant data on vaginal epithelial cell-mediated anti-Candida activity are available; however, a survey of such activity in adult women has not been conducted. The purpose of the present study was to evaluate the anti-Candida activity of epithelial cells collected from the human vaginal mucosa in a large population of women at different stages of the menstrual cycle, as well as from women with a history of RVVC.
Subjects and Methods
Subjects. Eighty-two healthy, nonpregnant women without a history of VVC and 10 women with RVVC in remission were recruited for this study. Among the 82 women who did not have RVVC, epithelial cells obtained from 29 women during the follicular phase of the menstrual cycle, from 14 during the ovulatory phase, and from 39 during the luteal phase were tested. Epithelial cells obtained from 11 of these women were tested at all 3 stages of the menstrual cycle over the course of a 2-year period. Venous blood was collected from all women, and serum samples were used to confirm the follicular and luteal stages of the menstrual cycle via progesterone concentrations measured at Wayne State University Clinical Endocrinology Laboratory (Detroit) by use of competitive enzyme immunoassays. The ovulatory stage was determined by a urine-based luteinizing hormone (LH) detection kit (OvuQuick; Quidel Pharmaceuticals) that identifies the 24-h periovulation period. Day of cycle from the start of menses and local cellular maturation indices from vaginal smears examined by Papanicolaou stain were also used to confirm the stage of the cycle. Of the women who participated in the study, 37% were white and 63% were black. The median age of all women was 40 years (range, 20-51 years). All women were confirmed to be free of vaginitis by vaginal swab culture on Sabouraud dextrose agar (Becton-Dickinson), had negative results of testing with potassium hydroxide stain of a vaginal smear, and lacked common symptoms of vaginitis. All yeast colonies from asymptomatic colonized women were tested for germ-tube formation and/or speciated by use of the API 20 AUX identification system (bioMérieux).
A diagnosis of RVVC was made on the basis of a history of >3 episodes of VVC during the course of 1 year. Women with RVVC were asymptomatic at the time of testing. Eighty percent of these women were receiving fluconazole maintenance therapy at the time of testing, to reduce the risk of further episodes.
Vaginal epithelial cell isolation. A vaginal lavage sample that consisted of 5 mL of sterile physiological saline continuously aspirated for 30-40 s was collected from each subject. The vaginal lavage was processed by centrifugation, and the cell pellet was stored at 270 C in cryopreservative medium (50% fetal bovine serum [FBS] , 25% RPMI 1640 medium, and 15% dimethyl sulfoxide; Gibco) until use. At the time of the assay, the cellular fraction was enriched for epithelioid cells by density gradient centrifugation, as described elsewhere [10] . The enriched population was resuspended in phytone-peptone (PP) medium (Becton-Dickinson) supplemented with 10% FBS (PP-FBS) and counted on a hemacytometer (Reichert) using trypan blue dye exclusion. Viability was generally .80%, and percentage of purity was generally .95% epithelial cells, as determined by counting of 5 separate fields of 100 cells.
Human vaginal epithelial cell line. A human vaginal epithelial cell line (VK2; R. Fichorova, Harvard Medical School, Boston) was used [13] . The VK2 cell line, immortalized with human papillomavirus 16E6E7, was maintained in keratinocyte serum-free medium (Gibco) supplemented with 50 mg/mL bovine pituitary extract, 0.1 ng/mL epidermal growth factor, 100 U/mL penicillin, and 100 mg/mL streptomycin and passaged every 3-4 days.
Growth inhibition assay. An established modified [ 3 H]glucose uptake assay was conducted [11] . In brief, C. albicans isolate strain 3153A, grown to stationary phase, was added to individual wells of a microtiter plate at 1 Â 10 5 cells/mL in a volume of 100 mL of PP-FBS medium. Epithelioid-enriched cells were then added in triplicate to a microtiter plate in a volume of 100 mL of PP-FBS at various ratios of effector to target cells (E:T ratio) based on viable cell numbers, beginning at 40:1 and serially diluted to 1.25:1. The culture was incubated at 37 C in 5% CO 2 for 9 h in the presence of 1 mCi [ 3 H]glucose (ICN Pharmaceuticals). After incubation, 100 mL of sodium perchloride (bleach) was added to each well for 5 min, the cell extracts were harvested, and the incorporated [ Statistical analysis. The unpaired Student's t test was used to analyze data. P , :05, calculated using a 2-tailed test, was considered to be significant.
Results
To further investigate the anti-Candida activity of vaginal epithelial cells, we tested the growth-inhibition potential of primary vaginal epithelial cells collected from a large number of women at different stages of the menstrual cycle, as well as from a small subset of patients with RVVC who were asymptomatic at the time of testing. Serum progesterone levels and vaginal cellular maturation indices confirmed the follicular and luteal stages of the menstrual cycle at the time of testing (table 1). Ovulation was confirmed by LH surge. Vaginal swab cultures indicated 14%-21% detectable asymptomatic colonization at various stages of the menstrual cycle; the majority of colonized women were colonized with C. albicans (.75%) (table 1). None of the women with RVVC had detectable yeast colonization.
The results illustrated in figure 1 show that epithelial cells collected from women without a history of VVC at each phase of the menstrual cycle, as well as those from patients with RVVC, were capable of inhibiting the growth of C. albicans in vitro. At high E:T ratios, vaginal epithelial cells from each stage of the menstrual cycle inhibited the growth of C. albicans at moderate levels (19%-29%). Cells from the ovulatory phase had the highest activity (27%-40%). In each case, a dose response was observed as E:T ratios decreased. Generally, no significant differences were seen in the activity of cells at each of the 3 stages of the menstrual cycle at any E:T ratio. The exception was a significant decrease in activity by cells collected during the follicular phase, compared with those collected during the luteal phase and evaluated at a 10:1 E:T ratio (P ¼ :0345). In contrast, vaginal epithelial cell anti-Candida activity for women with a history of RVVC was significantly reduced, compared with cells collected during the follicular and ovulatory phases of the menstrual cycle evaluated at E:T ratios of 10:1 (P , :0329) and 5:1 (P , :0085) and compared with cells collected during all stages of the menstrual cycle evaluated at E:T ratios of 2.5:1 (P , :0210) and 1.25:1 (P , :0428). The vaginal epithelial cell line exhibited a wider range of Candida inhibition at the same E:T ratios (.60% at 40:1 to ,10% at 5:1 and less).
Discussion
Although the role of Candida-specific T cells and antibodies at the vaginal mucosa in adaptive immunity has been challenged, as have the limited roles of PMNL and NK cells against C. albicans in the vagina [8, 11, 14] , vaginal epithelial cells from mice and nonhuman primates have recently been shown to inhibit the growth of C. albicans in vitro [10, 11] . This potentially important innate host defense mechanism has Results are expressed as percentage of inhibition by epithelial cells of total glucose uptake by C. albicans at various ratios of effector to target cells (E:T). The mean^SEM for individual tests and for 3 repeated tests of the vaginal cell line are shown. w, P , :05, compared with data from all stages of the menstrual cycle; e, P , :05, compared with data from follicular and ovulatory stages; t, P , :05, data from follicular stage compared with data from luteal stage. also been reported for human oral epithelial cells and epithelial cell lines but not for lymphoid cell lines [15] . The present study shows that human vaginal epithelial cells collected at various stages of the menstrual cycle from women without RVVC and a vaginal epithelial cell line also inhibit the growth of C. albicans in a dose-dependent manner. In fact, compared with anti-Candida activity by epithelial cells from the vaginal mucosa of mice and nonhuman primates [10, 11] , primary and immortalized human vaginal epithelial cells have similar levels of activity at all E:T ratios. In contrast, human, macaque, and mouse vaginal epithelial cell-mediated anti-Candida activity is considerably less than that the activity reported for human oral epithelial cells and may, in fact, be considered to be nonexistent in some women [15] . If epithelial cells do indeed represent an innate host defense mechanism, the lesser activity of vaginal epithelial cells, in comparison with that of oral epithelial cells, may account for the increased frequency of VVC, compared with oropharyngeal candidiasis, in otherwise healthy individuals. Perhaps a design that incorporated adherent monolayers of epithelial cells that simulate clinical conditions in the vagina would show more effective anti-Candida activity. However, such a design is not possible, because the fully differentiated epithelial cells collected from vaginal lavage samples are not adherent, despite their viability. To circumvent this, however, we tested several E:T ratios that offered a variety of conditions for monitoring cellular interactions with the yeast.
Except for some isolated instances, there appears to be no apparent hormonal effect on anti-Candida activity at the vaginal mucosa, although there was a trend toward higher activity during the ovulatory phase, when estrogen is elevated. Eleven women who did not have RVVC and whose cells were examined multiple times over the course of the menstrual cycle showed levels of anti-Candida activity that were consistent with this. In contrast, vaginal epithelial cells from mice and nonhuman primates displayed reduced anti-Candida activity when collected during a state of pseudoestrus [10, 11] . Therefore, in humans, the increased susceptibility to VVC while estrogen levels are increased would not be expected to involve reductions in epithelial cell anti-Candida activity but rather an as-yet-undefined host defense mechanism.
No specific pattern of higher or lower growth inhibition of C. albicans was seen in cells collected from women with vaginal yeast colonization (data not shown). Therefore, the presence of yeast in vivo does not appear to influence anti-Candida activity, although we recognize that a failure to find colonization at any sampling does not imply a lack of exposure or rule out the possibility that yeast is present but undetectable. Interestingly, oral epithelial cell-mediated anti-Candida activity is greater in the presence of higher levels of asymptomatic colonization [15] . On the other hand, vaginal epithelial cell-mediated anti-Candida activity in adolescents is lower than that in adults, despite the existence of a higher percentage of asymptomatic colonization ($30%) with high levels of fungal burden in adolescents (P.F., unpublished observations).
The mechanism of the epithelial cell-mediated anti-Candida activity currently is not fully understood. Murine vaginal and human oral epithelial cells function by cell contact; soluble factors have no role, and phagocytosis and surface phospholipids and proteins are not involved. On the other hand, the activity is abrogated by periodic acid, which suggests that surface carbohydrates have a role [12] . It is expected that human vaginal epithelial cells function in a similar manner.
Vaginal epithelial cells from women with RVVC who were in remission at the time of testing displayed anti-Candida activity similar to that of cells from women with no history of RVVC at high E:T ratios. However, at lower E:T ratios, epithelial cells from women with RVVC had significantly less activity than did cells from women without RVVC, regardless of the stage of the menstrual cycle at which cells were collected. These data may indicate a dysfunction in epithelial cells in women with RVVC, at least when Candida and epithelial cells approach equal numbers. We recognize that the activity is fairly weak and that the differences observed reflect the lower inhibition ranges. Nevertheless, if epithelial cells represent an innate vaginal host defense mechanism, weaker activity in women with RVVC may promote quicker overgrowth of Candida and contribute to susceptibility to infection. Testing of larger numbers of women with RVVC is needed to confirm this hypothesis. Testing of women with RVVC while they are symptomatic would also be of interest. However, infectious levels of Candida associated with epithelial cells interfere with the epithelial cell controls necessary for the growth inhibition assay.
In conclusion, this is the first evidence that human vaginal epithelial cells can inhibit the growth of C. albicans. The antiCandida activity of these cells, although detectable, is fairly weak, compared with that of oral epithelial cells. We hypothesize that, in the absence of a significant adaptive response against C. albicans, vaginal epithelial cells provide an innate host resistance mechanism to control commensalism but can be easily overwhelmed, resulting in frequent episodes of VVC. Furthermore, reduced levels of epithelial cell anti-Candida activity in women with RVVC may contribute to recurrent episodes.
